2 results
Approved WMOPending
To compare the objective response rate between patients with metastatic non-small cell lung cancer characterized by PDL-1 TPS<50% and low TMB and either actionable mutation, inactivating STK11, KEAP1 or NFE2L2 mutations, treated by…
Approved WMOPending
The primary objective of this study is to evaluate the clinical performance of the VENTANA PD-L1 (SP263) CDx Assay in terms of its ability to identify patients with non-squamous stage IV or recurrent NSCLC who may benefit from treatment with…